1: (ROOT (S (NP (NML (JJ Antiviral) (NN Drug)) (NN Cocktail)) (VP (VBZ Shows) (NP (NN Success)))))
2: (ROOT (S (NP (NML (NNP Hong) (NNP Kong)) (NNS scientists)) (VP (VBP have) (VP (VBN completed) (NP (NP (DT a) (JJ clinical) (NN study)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (S (VP (VBG administering) (NP (NP (DT this) (NN cocktail)) (PP (IN of) (NP (JJ antiviral) (NNS medications)))) (PP (IN to) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ mild) (NN coronavirus) (NNS symptoms))))))) (`` `) (VP (MD may) (ADVP (RB rapidly)) (VP (VB suppress) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NN virus))) (PP (IN in) (NP (NP (DT a) (NN patient) (POS 's)) (NN body))))))))))) (. .) ('' ')))
3: (ROOT (S (`` `) (S (NP (JJ Early) (JJ triple) (JJ antiviral) (NN therapy)) (VP (VBD was) (JJ safe) (CC and) (ADJP (JJ superior) (PP (IN to) (NP (NP (NN lopinavir)) (: -) (NP (NN ritonavir)) (ADVP (RB alone))))) (PP (PP (IN in) (VP (VBG alleviating) (NP (NNS symptoms)))) (CC and) (VP (VBG shortening) (NP (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (JJ viral) (NN shedding)) (CC and) (NP (NN hospital) (NN stay))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (JJ mild) (TO to) (JJ moderate)) (CD COVI-19)))))))))) (, ,) ('' ') (NP (DT the) (NN study) (NP (NNS authors))) (VP (VBD wrote) (, ,) (S (VP (VBG adding) (SBAR (IN that) (`` `) (S (NP (NP (JJ future) (JJ clinical) (NN study)) (PP (IN of) (NP (NP (DT a) (JJ double) (JJ antiviral) (NN therapy)) (PP (IN with) (NP (NP (NN interferon) (NN bet-1b)) (PP (IN as) (NP (DT a) (NN backbone)))))))) (VP (VBZ is) (VP (VBN warranted) ('' ') (PP (IN for) (NP (DT a) (JJ complete) (NN overview)))))))))) (. .)))
4: (ROOT (S (S (SBAR (IN As) (S (VP (VBN published) (PP (IN in) (NP (DT the) (NNP Lancet)))))) (NP (DT this) (NML (CD 127) (NN patient)) (NML (JJ open) (NN label)) (NN study)) (VP (VBD had) (NP (NP (NP (CD 86) (NNS patients)) (VP (ADVP (RB randomly)) (VP (VBN assigned) (PP (IN to) (NP (DT the) (JJ experimental) (NN cocktail) (NN treatment) (NN group)))))) (CC and) (VP (NP (CD 41)) (PP (IN to) (NP (NP (DT the) (NN control) (NN group)) (SBAR (WHNP (WP who)) (S (ADVP (RB only)) (VP (VBD received) (NP (NP (DT the) (NML (NNP HIV) (NN therapy)) (NN drug)) (NP (FW lopinavi) (HYPH -) (NN ritonavir)))))))))))) (: ;) (S (NP (NP (NML (NN age) (, ,) (NN gender) (, ,) (CC and) (NN baseline)) (NNS demographics)) (PP (IN in) (NP (DT each) (NN group)))) (VP (VBD were) (ADJP (JJ similar)) (PP (IN with) (S (NP (NP (NN fever)) (CC and) (NP (DT a) (JJ dry) (NN cough))) (VP (VBG being) (PP (IN among) (NP (DT the) (ADJP (RBS most) (JJ common)) (NNS symptoms)))))))) (. .)))
5: (ROOT (S (PP (IN After) (NP (NP (QP (RB only) (CD seven)) (NNS days)) (PP (IN of) (S (VP (VBG being) (VP (VBN administered) (NP (DT the) (NNS experiments) (NN cocktail) (NN treatment)))))))) (NP (DT the) (NNS patients)) (VP (VBD tested) (ADJP (JJ negative)) (PP (IN for) (NP (CD COVI-19))) (PP (VBG according) (PP (IN to) (NP (DT the) (NNS researchers))))) (. .)))
6: (ROOT (S ('' `) (S (PP (IN For) (NP (NP (DT the) (JJ primary) (NN endpoint)) (PP (IN of) (NP (NN time))) (PP (PP (IN from) (NP (NP (NN start)) (PP (IN of) (NP (NN study) (NN treatment))))) (PP (IN to) (NP (JJ negative) (JJ nasopharyngeal) (NN swab)))))) (, ,) (NP (DT the) (NN combination) (NN group)) (VP (VBD had) (NP (NP (DT a) (ADJP (RB significantly) (JJR shorter)) (JJ median) (NN time)) (PP (IN than) (NP (DT the) (NN control) (NN group)))))) (, ,) ('' ') (NP (DT the) (NN study) (NNS authors)) (VP (VBD noted)) (. .) ('' ')))
7: (ROOT (S (PP (IN For) (NP (DT the) (JJ virological) (NN outcome))) (, ,) (NP (DT the) (NN combination) (NN treatment)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (ADJP (RB significantly) (JJR shorter)) (NN time)) (PP (IN to) (NP (JJ negative) (JJ viral) (NN load)))) (PP (PP (IN in) (NP (NP (DT all) (NNS specimens)) (SBAR (WHADVP (WRB when)) (S (VP (VBN assessed) (ADVP (RB individually))))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (DT all) (NNS specimens)) (VP (VBN combined))))))))) (. .)))
8: (ROOT (S (NP (DT All) (NN urine) (NNS samples)) (VP (VBD tested) (S (ADJP (JJ negative))) (PP (IN for) (NP (JJ viral) (NN load)))) (. .) ('' ')))
9: (ROOT (S (S (NP (NP (ADJP (RB Previously) (VBN established)) (JJ side) (NNS effects)) (PP (IN of) (NP (DT the) (NNS medications)))) (VP (VBD were) (VP (VBG being) (ADVP (RB closely)) (VP (VBN monitored))))) (, ,) (SBAR (ADVP (RB however)) (S (S (NP (DT the) (NNS drugs)) (VP (VBP have) (NP (NP (DT a) (ADJP (JJ long) (VBG standing)) (NN track) (NN record)) (PP (IN for) (NP (NN safety)))) (PP (VBG according) (PP (IN to) (NP (JJ medical) (NNS officials)))))) (, ,) (CC and) (S (PP (PP (IN on) (ADJP (JJ average))) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (NN cocktail) (NN group))))) (VP (VBD felt) (ADJP (RBR better)) (PP (IN after) (NP (CD 4) (NNS days))))))) (. .)))
10: (ROOT (S (-LRB- `) (S (PP (IN Despite) (NP (NP (DT the) (NN concern)) (PP (IN of) (NP (NP (JJ major) (NN side) (NNS effects)) (VP (VBG arising) (PP (IN from) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (CD three) (NNS drugs)))))))))) (, ,) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (NN incidence)) (PP (IN of) (NP (JJ adverse) (NNS events))))) (PP (IN between) (NP (NN treatment) (NNS groups)))) (VP (VBD were) (VP (VBN reported) (PP (IN in) (NP (NP (PRP$ our) (NN cohort)) (PP (IN of) (NP (CD 127) (NNS patients)))))))) (, ,) ('' ') (NP (DT the) (NN study) (NNS authors)) (VP (VBD wrote)) (. .)))
11: (ROOT (S ('' `) (NP (DT No) (NN haemolysis)) (VP (VBD occurred) (PP (IN from) (NP (NP (DT the) (JJ short) (NN duration)) (PP (IN of) (NP (NML (JJ low) (NN dose)) (NN ribavirin)))))) (. .)))
12: (ROOT (S (NP (PRP We)) (VP (VBD did) (RB not) (VP (VP (VB use) (NP (JJ triple) (NN combination)) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD started) (NP (NN treatment)) (PP (NP (NP (CD 7) (NNS days)) (QP (CC or) (JJR more))) (PP (IN after) (NP (NN symptom) (NN onset))))))))) (PP (IN because) (IN of) (NP (NP (DT the) (NNS concerns)) (PP (IN about) (NP (NP (DT the) (JJ proinflammatory) (NN side) (NNS effects)) (PP (IN of) (NP (NN interferon) (NN bet-1b))))))) (: -) (PP (ADVP (IN despite) (ADVP (IN that) (ADVP (RB at) (RBS most)))) (, ,) (NP (CD three) (NNS doses)) (VP (VBD were) (VP (VBN used) (PP (IN for) (NP (DT each) (NN patient))))))) (, ,) ('' ') (NP (PRP they)) (VP (VBD added) (, ,) (S (VP (VBG noting) (SBAR (IN that) (`` `) (S (S (NP (NN liver) (NN dysfunction)) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (QP (RB about) (CD 14)) (NN %)) (PP (IN of) (NP (DT these) (NNS patients)))))))) (CC and) (S (NP (PRP it)) (VP (VBD was) (ADJP (ADJP (JJ mild)) (CC and) (ADJP (NN sel) (HYPH -) (JJ limiting))) (, ,) (PP (IN except) (PP (IN in) (NP (NP (NP (CD one) (NN patient)) (PP (IN in) (NP (DT the) (NN control) (NN group)))) (, ,) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (DT the) (JJ biochemical) (NN hepatitis)) (VP (VBD warranted) (NP (NP (DT the) (NN discontinuation)) (PP (IN of) (NP (NP (NN lopinavir)) (: -) (NN ritonavir) (NN treatment))))))))))))))))))) (. .) ('' ')))
13: (ROOT (S (NP (DT This) (NN study)) (VP (VBD was) (ADVP (RB independently)) (VP (VBN reviewed) (PP (IN by) (NP (NP (NNS experts)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD concurred) (SBAR (IN that) (S (NP (DT these) (NNS findings)) (VP (VBD were) (ADJP (JJ positive)))))) (, ,) (CC but) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJR larger) (JJ clinical) (NNS trials)) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (NP (JJR greater) (NN certainty)) (PP (IN of) (NP (NP (DT the) (NN cocktail) (POS 's)) (NN effectiveness) (CC and) (NN safety))))))))))))))))) (. .)))
14: (ROOT (S (S (NP (JJ Other) (NNS diseases)) (VP (VBP have) (NP (NP (DT a) (NN record)) (PP (IN of) (S (VP (VBG being) (VP (VBN treated) (ADVP (RB successfully)) (PP (IN with) (NP (NP (DT a) (NN cocktail)) (PP (IN of) (NP (NNS drugs)))))))))))) (, ,) (S (NP (DT the) (NNS experts)) (VP (VBP believe) (SBAR (IN that) (S (NP (PRP it)) (VP (MD may) (ADVP (RB also)) (VP (VB be) (NP (NP (DT the) (NN case)) (PP (IN for) (NP (CD COVI-19)))))))))) (, ,) (NP (NNS results)) (VP (VP (VBP are) (ADJP (JJ promising))) (CC and) (VP (VBP warrant) (S (VP (VBG adding) (NP (JJ interferon) (NN beta)) (PP (IN to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (NP (ADJP (NN evidence) (VBN based)) (NNS treatments)) (PP (IN for) (NP (DT the) (NN coronavirus))))))))))) (. .)))
